Some cancers develop from defective B cells. Bruton’s tyrosine kinase inhibitors work by targeting a protein critical to the lifecycle of those B cells. Learn from Michael Wang, M.D., how these drugs work and why they’re considered a breakthrough for treating B-cell lymphomas.
Comments are closed.